HATFIELD, England, May 20, 2011 /PRNewswire/ -- Eisai announced today that 10 abstracts highlighting new study results in thyroid cancer, metastatic breast cancer, ovarian cancer and other cancers will be presented during the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from June 3 to June 7, 2011.
These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's commitment to help address the diverse needs of patients and their families affected by cancer.
"We have a strong and growing commitment to oncology and in particular cancers affecting women," said Takashi Owa, Ph.D., President, Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Inc. "Eisai has a significant portfolio of oncology compounds and therapies that are representative of our human health care mission -- to help address unmet medical needs and increase benefits to patients and their families."
The following Eisai abstracts are accepted for presentation at this year's ASCO meeting:
Product Abstract Name Lenvatinib A Phase II Trial of the Multi-Targeted Kinase Inhibitor (E7080) E7080 in Advanced Radioiodine (RAI)-Refractory Abstract No: Differentiated Thyroid Cancer (DTC) 5503 Oral Session Lenvatinib Assessment of Clinical Activity of E7080, a Multi- (E7080) Targeted Kinase Inhibitor, in Patients with Advanced Abstract No: Melanoma Treated in Two Phase I trials 8527 Poster discussion session Lenvatinib The Effect of E7080, a VEGFR and FGFR Tyrosine Kinase (E7080) Inhibitor (TKI), on BRAF Wild-Type Melanoma Abstract No: Poster Presentation 8566 Lenvatinib Mechanism of Antitumor Activity of E7080, a Selective (E7080) VEGFR and FGFR Tyrosine Kinase Inhibitor (TKI) in Abstract No: Combination with Selective Mutant BRAF Inhibition 8567 Poster Session Lenvatinib Molecular Profiling of Melanoma tumor biopsies to E7080 identify a response signature to the multi-RTK inhibitor Abstract No. E7080 8595 Farletuzumab Phase I Safety Study of Farletuzumab, Carboplatin and Abstract No: Peglyated Liposomal Doxorubicin (PLD) in Subjects with 5056 Platinum-Sensitive Epithelial Ovarian Cancer (EOC) Poster Session MORAb-004 A First-in-Human Phase I Study of MORAb-004 (MOR4), a Abstract No: humanized monoclonal antibody recognizing TEM-1 3086 (endosialin), in patients with solid tumors Poster Session Eribulin The Relationship Between Age and Survival Outcomes for Mesylate Eribulin in Metastatic Breast Cancer Abstract No: Poster Session 1060 Eribulin Eribulin Dosing in Patients with Advanced Solid Tumors Mesylate and Hepatic Impairment Abstract No: Poster Session 2544 Polifeprosan 20 Effects of Surgery with BCNU Wafer Placement on with carmustine Neurocognitive Function in Patients with One to Three implant Brain Metastases Abstract No: Poster Discussion 2015
Notes to Editors
Eisai Oncology is dedicated to discovering, developing and producing innovative oncology therapies that can help make a difference and impact the lives of patients and their families. This passion for people is part of Eisai's human health care (hhc) mission, which strives for better understanding of the needs of patients and their families to increase the benefits health care provides. Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, biologic and supportive care agents for cancer across multiple indications.
Eisai is one of the world's leading R&D-based pharmaceutical companies that has defined its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:
- Integrative Neuroscience: Alzheimer's disease, multiple sclerosis, neuropathic pain, epilepsy, depression, etc
- Integrative Oncology: Anticancer therapies; tumour regression, tumour suppression, antibodies, etc and Supportive cancer therapies; pain relief, nausea, etc
- Vascular/Immunological Reaction: Acute coronary syndrome, atherothrombotic disease, sepsis, rheumatoid arthritis, psoriasis, Crohn's disease, etc
With operations in the U.S., Asia, Europe and its domestic home market of Japan, we employ more than 10,000 people worldwide, and reported consolidated sales of over GBP3.53 billion in FY2007, an increase of 8.9% year on year. In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Hungary, Slovakia and the Netherlands.
For further information please visit our web site http://www.eisai.com